Synopsis
Synopsis
0
EU WC
0
KDMF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Eqvalan
2. Ivermectin
3. Ivomec
4. Mectizan
5. Mk 933
6. Mk-933
7. Mk933
8. Stromectol
1. Ivermectin
2. Dihydroavermectin B1a
3. 70288-86-7
4. 22,23-dihydroavermectin B1a
5. 70161-11-4
6. Ivermectin Component B1a
7. 71827-03-7
8. Avermectin H2b1a
9. 5-o-demethyl-22,23-dihydroavermectin A1a
10. Chebi:63941
11. 91y2202ouw
12. (2ae,4e,5's,6s,6'r,7s,8e,11r,13r,15s,17ar,20r,20ar,20bs)-6'-[(2s)-butan-2-yl]-20,20b-dihydroxy-5',6,8,19-tetramethyl-17-oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2h,7h-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-o-(2,6-dideoxy-3-o-methyl-alpha-l-arabino-hexopyranosyl)-3-o-methyl-alpha-l-arabino-hexopyranoside
13. Mk-933
14. (1r,4s,5's,6r,6'r,8r,10e,12s,13s,14e,16e,20r,21r,24s)-6'-[(2s)-butan-2-yl]-21,24-dihydroxy-12-[(2r,4s,5s,6s)-5-[(2s,4s,5s,6s)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-5',11,13,22-tetramethylspiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2'-oxane]-2-one
15. Ivermectin B1a-d2
16. C48h74o14
17. Unii-91y2202ouw
18. 22,23-dihydroavermectin B(1)a
19. Ncgc00163233-01
20. Ivermectin (ivm)
21. Ivm
22. Einecs 276-046-2
23. Dihydro Avermectin Bla
24. Brn 4643153
25. 22,23-dihydro-5-o-demethylavermectin A1a
26. H2b1a
27. Prestwick3_000156
28. Dsstox_cid_3181
29. Ivermectin (mk-0933)
30. Dsstox_rid_76909
31. Dsstox_gsid_23181
32. Bspbio_000292
33. Schembl312795
34. Bpbio1_000322
35. Chembl263291
36. Dtxsid8023181
37. Chebi:94551
38. Hms2089m09
39. Hms2095o14
40. Hms3712o14
41. Wca82703
42. Tox21_112034
43. Bdbm50409816
44. Mfcd30496678
45. S1351
46. Akos027470116
47. Ivermectin Component B1a [mi]
48. Zinc238808778
49. Zinc252286706
50. Ac-6014
51. Ccg-220156
52. Ncgc00186639-01
53. Ncgc00186639-03
54. As-14167
55. Bi166167
56. Cas-71827-03-7
57. Hy-126937
58. Ab00513813
59. Cs-0108408
60. 22,23-dihydroavermectin B1a; Ivermectin
61. Ab00513813-02
62. Ab00513813-03
63. Ab00513813_04
64. Avermectin A1a, 22,23-dihydro-5-o-demethyl-
65. 288i867
66. Ivermectin, Antibiotic For Culture Media Use Only
67. Q-201262
68. Brd-k24652731-001-02-7
69. Brd-k85554912-001-08-9
70. Q27132923
71. Ivermectin, British Pharmacopoeia (bp) Reference Standard
72. Ivermectin, European Pharmacopoeia (ep) Reference Standard
73. Ivermectin, United States Pharmacopeia (usp) Reference Standard
74. Ivermectin, Pharmaceutical Secondary Standard; Certified Reference Material
75. (2ae,4e,5's,6s,6'r,7s,8e,11r,13r,15s,17ar,20r,20ar,20bs)-6'-[(2s)-butan-2-yl]-20,20b-dihydroxy-5',6,8,19-tetramethyl-17
76. Clooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-o-(2,6-dideoxy-3-o-methyl-alpha-l-arabino-hexopyranosyl)-3-o-methyl-alpha-l-arabino-hexopyranoside
Molecular Weight | 875.1 g/mol |
---|---|
Molecular Formula | C48H74O14 |
XLogP3 | 4.1 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 14 |
Rotatable Bond Count | 8 |
Exact Mass | 874.50785703 g/mol |
Monoisotopic Mass | 874.50785703 g/mol |
Topological Polar Surface Area | 170 Ų |
Heavy Atom Count | 62 |
Formal Charge | 0 |
Complexity | 1680 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 20 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 3 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Treatment of rosacea
Antiparasitic Agents
Drugs used to treat or prevent parasitic infections. (See all compounds classified as Antiparasitic Agents.)
Insecticides
Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)
D - Dermatologicals
D11 - Other dermatological preparations
D11A - Other dermatological preparations
D11AX - Other dermatologicals
D11AX22 - Ivermectin
P - Antiparasitic products, insecticides and repellents
P02 - Anthelmintics
P02C - Antinematodal agents
P02CF - Avermectines
P02CF01 - Ivermectin
Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-02-08
Pay. Date : 2012-12-18
DMF Number : 21624
Submission : 2008-05-08
Status : Active
Type : II
Certificate Number : CEP 1999-176 - Rev 06
Issue Date : 2025-01-10
Type : Chemical
Substance Number : 1336
Status : Valid
Registration Number : 304MF10048
Registrant's Address : 46 Waisha Road, Jiaojiang District, Taizhou City, Zhejiang Province, P. R. China 318000
Initial Date of Registration : 2022-03-02
Latest Date of Registration :
NDC Package Code : 58623-0047
Start Marketing Date : 2014-10-24
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
VMF Number : 5553
Submission : 1995-12-14
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-01-09
Pay. Date : 2012-12-14
DMF Number : 21395
Submission : 2008-03-05
Status : Active
Type : II
Certificate Number : R1-CEP 1998-138 - Rev 05
Issue Date : 2020-02-28
Type : Chemical
Substance Number : 1336
Status : Valid
Registration Number : 304MF10006
Registrant's Address : Estrada Coronel Nicolau de Mesquita Taipa, Macau S. A. R. China
Initial Date of Registration : 2022-01-11
Latest Date of Registration :
NDC Package Code : 55018-121
Start Marketing Date : 1998-07-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-04-06
Pay. Date : 2022-01-13
DMF Number : 36494
Submission : 2021-11-15
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17673
Submission : 2004-07-18
Status : Inactive
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12755
Submission : 1997-11-21
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17673
Submission : 2004-07-18
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-01-09
Pay. Date : 2012-12-14
DMF Number : 21395
Submission : 2008-03-05
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2022-04-06
Pay. Date : 2022-01-13
DMF Number : 36494
Submission : 2021-11-15
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-02-08
Pay. Date : 2012-12-18
DMF Number : 21624
Submission : 2008-05-08
Status : Active
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12755
Submission : 1997-11-21
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38553
Submission : 2023-06-27
Status : Active
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13037
Submission : 1998-06-15
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info :
Registration Country : Norway
Brand Name : Scatol
Dosage Form : Tablet
Dosage Strength : mg
Packaging : Blisterpakning 4item
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Scatol
Dosage Form : Tablet
Dosage Strength : mg
Packaging : Blisterpakning 12item
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Sweden
Brand Name : Soolantra
Dosage Form : CREAM
Dosage Strength : 10 MG / G
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Norway
Brand Name : Soolantra
Dosage Form : Cream
Dosage Strength : 10 mg/g
Packaging : Tube of plastic
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Switzerland
Brand Name : Soolantra
Dosage Form : Cream
Dosage Strength : 10mg/g
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Norway
Brand Name : Ivermectin Medical Valley
Dosage Form : Tablet
Dosage Strength : mg
Packaging : Blisterpakning 4item
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Ivermectin Medical Valley
Dosage Form : Tablet
Dosage Strength : mg
Packaging : Blisterpakning 10item
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Ivermectin Orifarm
Dosage Form : Tablet
Dosage Strength : mg
Packaging : Blisterpakning 4item
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Ivermectin STADA
Dosage Form : Tablet
Dosage Strength : mg
Packaging : Blisterpakning 4item
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Reply
28 Feb 2025
Reply
15 Oct 2024
Reply
27 Sep 2024
Reply
03 Jan 2024
Reply
03 Jul 2023
Reply
06 Jun 2023
Reply
06 Apr 2023
Reply
13 Mar 2023
Reply
21 Mar 2023
Reply
17 Jun 2022
Reply
11 Mar 2022
Reply
15 Jul 2021
Reply
19 Jan 2021
Reply
31 Dec 2020
Reply
15 Jul 2020
Patents & EXCLUSIVITIES
Patent Expiration Date : 2034-03-13
US Patent Number : 10206939
Drug Substance Claim :
Drug Product Claim :
Application Number : 206255
Patent Use Code : U-1631
Delist Requested :
Patent Use Description : TREATMENT OF INFLAMMAT...
Patent Expiration Date : 2034-03-13
Patent Expiration Date : 2034-03-13
US Patent Number : 9782425
Drug Substance Claim :
Drug Product Claim :
Application Number : 206255
Patent Use Code : U-1631
Delist Requested :
Patent Use Description : TREATMENT OF INFLAMMAT...
Patent Expiration Date : 2034-03-13
Patent Expiration Date : 2034-03-13
US Patent Number : 9233117
Drug Substance Claim :
Drug Product Claim :
Application Number : 206255
Patent Use Code : U-1631
Delist Requested :
Patent Use Description : TREATMENT OF INFLAMMAT...
Patent Expiration Date : 2034-03-13
Patent Expiration Date : 2034-03-13
US Patent Number : 9089587
Drug Substance Claim :
Drug Product Claim :
Application Number : 206255
Patent Use Code : U-1631
Delist Requested :
Patent Use Description : TREATMENT OF INFLAMMAT...
Patent Expiration Date : 2034-03-13
Patent Expiration Date : 2034-03-13
US Patent Number : 9233118
Drug Substance Claim :
Drug Product Claim :
Application Number : 206255
Patent Use Code : U-1631
Delist Requested :
Patent Use Description : TREATMENT OF INFLAMMAT...
Patent Expiration Date : 2034-03-13
Patent Expiration Date : 2024-04-22
Date Granted : 2012-08-28
Brand Name : ROSIVER
Patent Number : 2522579
Filing Date : 2004-04-22
Strength per Unit : 1% w / w
Dosage Form : CREAM
Human Or VET : Human
Route of Administration : TOPICAL
Patent Expiration Date : 2024-04-22
Date Granted : 2012-08-28
Patent Expiration Date : 2005-06-28
Date Granted :
Brand Name :
Patent Number : 1238543
Filing Date :
Strength per Unit :
Dosage Form :
Human Or VET :
Route of Administration :
Patent Expiration Date : 2005-06-28
Date Granted :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2005-11-15
Date Granted :
Brand Name :
Patent Number : 1244738
Filing Date :
Strength per Unit :
Dosage Form :
Human Or VET :
Route of Administration :
Patent Expiration Date : 2005-11-15
Date Granted :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2006-04-11
Date Granted :
Brand Name :
Patent Number : 1252359
Filing Date :
Strength per Unit :
Dosage Form :
Human Or VET :
Route of Administration :
Patent Expiration Date : 2006-04-11
Date Granted :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2003-06-24
Date Granted :
Brand Name :
Patent Number : 1206414
Filing Date :
Strength per Unit :
Dosage Form :
Human Or VET :
Route of Administration :
Patent Expiration Date : 2003-06-24
Date Granted :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2007-02-20
Date Granted :
Brand Name :
Patent Number : 1265966
Filing Date :
Strength per Unit :
Dosage Form :
Human Or VET :
Route of Administration :
Patent Expiration Date : 2007-02-20
Date Granted :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2007-04-17
Date Granted :
Brand Name :
Patent Number : 1267844
Filing Date :
Strength per Unit :
Dosage Form :
Human Or VET :
Route of Administration :
Patent Expiration Date : 2007-04-17
Date Granted :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2007-04-17
Date Granted :
Brand Name :
Patent Number : 1267844
Filing Date :
Strength per Unit :
Dosage Form :
Human Or VET :
Route of Administration :
Patent Expiration Date : 2007-04-17
Date Granted :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2008-07-09
Date Granted :
Brand Name :
Patent Number : 1285842
Filing Date :
Strength per Unit :
Dosage Form :
Human Or VET :
Route of Administration :
Patent Expiration Date : 2008-07-09
Date Granted :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
91
PharmaCompass offers a list of Ivermectin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ivermectin manufacturer or Ivermectin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ivermectin manufacturer or Ivermectin supplier.
PharmaCompass also assists you with knowing the Ivermectin API Price utilized in the formulation of products. Ivermectin API Price is not always fixed or binding as the Ivermectin Price is obtained through a variety of data sources. The Ivermectin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Ivermectin B1a manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ivermectin B1a, including repackagers and relabelers. The FDA regulates Ivermectin B1a manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ivermectin B1a API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ivermectin B1a manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ivermectin B1a supplier is an individual or a company that provides Ivermectin B1a active pharmaceutical ingredient (API) or Ivermectin B1a finished formulations upon request. The Ivermectin B1a suppliers may include Ivermectin B1a API manufacturers, exporters, distributors and traders.
click here to find a list of Ivermectin B1a suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Ivermectin B1a DMF (Drug Master File) is a document detailing the whole manufacturing process of Ivermectin B1a active pharmaceutical ingredient (API) in detail. Different forms of Ivermectin B1a DMFs exist exist since differing nations have different regulations, such as Ivermectin B1a USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Ivermectin B1a DMF submitted to regulatory agencies in the US is known as a USDMF. Ivermectin B1a USDMF includes data on Ivermectin B1a's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ivermectin B1a USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Ivermectin B1a suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Ivermectin B1a Drug Master File in Japan (Ivermectin B1a JDMF) empowers Ivermectin B1a API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Ivermectin B1a JDMF during the approval evaluation for pharmaceutical products. At the time of Ivermectin B1a JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Ivermectin B1a suppliers with JDMF on PharmaCompass.
A Ivermectin B1a CEP of the European Pharmacopoeia monograph is often referred to as a Ivermectin B1a Certificate of Suitability (COS). The purpose of a Ivermectin B1a CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Ivermectin B1a EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Ivermectin B1a to their clients by showing that a Ivermectin B1a CEP has been issued for it. The manufacturer submits a Ivermectin B1a CEP (COS) as part of the market authorization procedure, and it takes on the role of a Ivermectin B1a CEP holder for the record. Additionally, the data presented in the Ivermectin B1a CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Ivermectin B1a DMF.
A Ivermectin B1a CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Ivermectin B1a CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Ivermectin B1a suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ivermectin B1a as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Ivermectin B1a API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Ivermectin B1a as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Ivermectin B1a and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ivermectin B1a NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Ivermectin B1a suppliers with NDC on PharmaCompass.
Ivermectin B1a Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ivermectin B1a GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ivermectin B1a GMP manufacturer or Ivermectin B1a GMP API supplier for your needs.
A Ivermectin B1a CoA (Certificate of Analysis) is a formal document that attests to Ivermectin B1a's compliance with Ivermectin B1a specifications and serves as a tool for batch-level quality control.
Ivermectin B1a CoA mostly includes findings from lab analyses of a specific batch. For each Ivermectin B1a CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ivermectin B1a may be tested according to a variety of international standards, such as European Pharmacopoeia (Ivermectin B1a EP), Ivermectin B1a JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ivermectin B1a USP).